Search results for " disease progression"

showing 10 items of 81 documents

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

2014

Importance There is an urgent need to identify reliable biomarkers of amyotrophic lateral sclerosis (ALS) progression for clinical practice and pharmacological trials. Objectives To correlate several hematological markers evaluated at diagnosis with ALS outcome in a population-based series of patients (discovery cohort) and replicate the findings in an independent validation cohort from an ALS tertiary center. Design, Setting, and Participants The discovery cohort included 712 patients with ALS from the Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis from January 1, 2007, to December 31, 2011. The validation cohort comprised 122 patients with ALS at different stages of…

MaleanalysisGastroenterologyCohort Studieschemistry.chemical_compoundAdult Aged Aged; 80 and over Amyotrophic Lateral Sclerosis; blood/mortality/pathology Biological Markers; blood Cohort Studies Creatinine; blood Disease Progression Female Humans Italy Lymphocyte Count Male Middle Aged Outcome Assessment (Health Care) Predictive Value of Tests Prognosis Sensitivity and Specificity Serum Albumin; analysisblood/mortality/pathologyOutcome Assessment Health Care80 and overAged 80 and overeducation.field_of_studybiologymedicine.diagnostic_testHazard ratioMiddle AgedPrognosisItalyErythrocyte sedimentation rateCreatinineCohortDisease ProgressionSettore MED/26 - NeurologiaBiological MarkersFemaleCohort studyAdultmedicine.medical_specialtyPopulationSerum albuminSensitivity and SpecificityOutcome Assessment (Health Care)bloodPredictive Value of TestsInternal medicinemedicineHumansLymphocyte CounteducationSerum AlbuminAgedCreatininebusiness.industryAmyotrophic Lateral SclerosisAlbuminchemistryImmunologybiology.proteinNeurology (clinical)ALSbusinessBiomarkersJAMA neurology
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct

Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment

2006

<i>Background:</i> Different rates and cognitive predictors of conversion to dementia have been reported in subjects with different kinds of mild cognitive impairment (MCI). <i>Methods:</i> A prospective, 24-month follow-up study, involving 269 subjects who strictly fulfilled criteria for the amnestic MCI. <i>Results:</i> Conversion rate to dementia was 21.4% per year. Seventy-nine out of the 83 individuals who developed dementia were affected by probable Alzheimer’s disease (AD). Among others, at the 24-month follow-up 24.1% were still affected by amnestic MCI, 13.3% had changed their neuropsychological profile of impairment and 17.2% were cognitively no…

Malemedicine.medical_specialtyClinical Dementia RatingCognitive NeuroscienceAudiologyPattern RecognitionNeuropsychological TestsCohort StudiesAlzheimer DiseasePredictive Value of TestsAlzheimer's disease Dementia Mild cognitive impairment NeurospychologymedicineDementiaMemory impairmentHumansMemory disorderProspective StudiesPsychiatryHumans; Alzheimer Disease; Disease Progression; Aged; Predictive Value of Tests; Cognition Disorders; Italy; Verbal Learning; Prospective Studies; Pattern Recognition Visual; Cohort Studies; Follow-Up Studies; Dementia; Neuropsychological Tests; Amnesia; Female; MaleAgedAlzheimer’s disease Mild cognitive impairment Dementia NeurospychologyCognitive disorderNeuropsychologyMild cognitive impairmentCognitionVerbal LearningAlzheimer's diseaseNeurospychologymedicine.diseasePsychiatry and Mental healthPattern Recognition VisualItalyDisease ProgressionFemaleSettore MED/26 - NeurologiaDementiaAmnesiaGeriatrics and GerontologyAlzheimer's diseasePsychologyCognition DisordersVisualFollow-Up Studies
researchProduct

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome.

2016

Obstructive sleep apnea syndrome (OSAS) is associated with an elevated risk of cardiovascular events and stroke. Matrix metalloproteinases (MMPs) are endopeptidases involved in extracellular matrix degradation and then in the development and progression of cardiovascular diseases. Our aim was to evaluate plasma levels of gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in a group of subjects with OSAS. We enrolled 48 subjects (36 men and 12 women; mean age 49.7 ± 14.68 yrs) with OSAS diagnosed with a 1-night cardiorespiratory study and then we subdivided these subjects into two subgroups according to the apnea/hypopnea index (AHI): Low (L = 21 subjects with AHI …

Malemedicine.medical_specialtyGelatinasesSettore MED/09 - Medicina InternaPhysiologyMMP-2; MMP-9; obstructive sleep apnea; TIMP-1; TIMP-2; Disease Progression; Female; Gelatinases; Humans; Male; Middle Aged; Sleep Apnea Obstructive; Tissue Inhibitor of Metalloproteinase-1; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)030204 cardiovascular system & hematologyMatrix metalloproteinaseGastroenterologyTIMP-203 medical and health sciencesTIMP-10302 clinical medicinePhysiology (medical)Internal medicinemedicineHumansStrokeobstructive sleep apneaOxygen saturation (medicine)Sleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1MMP-2business.industryApneaCardiorespiratory fitnessHematologyMiddle Agedmedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneaEndocrinology030228 respiratory systemGelatinaseGelatinasesDisease ProgressionFemalemedicine.symptomMMP-9Settore MED/36 - Diagnostica Per Immagini E RadioterapiaCardiology and Cardiovascular MedicinebusinessHypopneaHumanClinical hemorheology and microcirculation
researchProduct

When the amnestic mild cognitive impairment disappears: characterisation of the memory profile

2009

BACKGROUND/OBJECTIVES: Subjects affected by mild cognitive impairment (MCI) may improve during the observation period. This is the first study investigating qualitative features of memory deficits in subjects affected by reversible MCI [reversible cognitive impairment (RCI)]. METHODS: Baseline cognitive and memory performances of 18 subjects affected by amnestic MCI who had normalized cognitive performances at follow-ups were compared with those of 76 amnestic MCI subjects who still showed impaired cognitive performances at the 24-month follow-up (MCI) and with those of a group of 87 matched control subjects (normal controls). RESULTS: Compared with normal controls the memory deficit in the…

MalememorianeuropsychologyAudiologyNeuropsychological TestsAlzheimer diseaseMemoryMild cognitive impairmentNeuropsychologyPreclinical dementiadeterioramento cognitivo lieveLong-term memoryCognitive disorderNeuropsychologypreclinical dementiaCognitionGeneral MedicinePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMemory Short-TermDisease ProgressionFemaleSettore MED/26 - Neurologiamedicine.symptomAlzheimer's diseasePsychologymedicine.medical_specialtyCognitive NeuroscienceAmnesiaHumans; Alzheimer Disease; Disease Progression; Aged; Mental Recall; Cognition Disorders; Memory; Memory Short-Term; Recognition (Psychology); Psychomotor Performance; Follow-Up Studies; Neuropsychological Tests; Amnesia; Female; MaleRecognition (Psychology)M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICAbehavioral disciplines and activitiesmild cognitive impairmentAlzheimer DiseaseMemorymental disordersNeuropsychologiamedicineHumansMemory disorderAgedMED/26 - NEUROLOGIARecognition Psychologymedicine.diseaseMCInervous system diseasesShort-TermMental Recallmild cognitive impairment; neuropsychology; memory; preclinical dementia; Alzheimer diseaseAmnesiaMED/09 - MEDICINA INTERNACognition Disordershuman activitiesNeurosciencePsychomotor PerformanceFollow-Up Studies
researchProduct

Role of HLA-B α-3 domain amino acid position 194 in HIV disease progression

2013

HLA class I molecules play a role in the regulation of innate immune response. Therefore, the interaction of HLA class I molecules with different activating and inhibitory receptors leads to balancing the immune response. Among the different family of receptors, NK receptors KIR3DL1/S1 and LIR1, play a major role. Aim of this study was to evaluate the role of amino acid polymorphic positions of HLA class I molecules interacting with NK receptors in HIV progression. In order to minimize the influence of viral variability, a cohort of children with a nosocomial monophyletic HIV-1 infection from the Benghazi Children Hospital has been evaluated. To assess the role of single amino acid position…

Models MolecularGene ExpressionKIR3DS1HIV InfectionsPeptide bindingLeukocyte Immunoglobulin-like Receptor B1ModelsImmunologicReceptorsInnateReceptors ImmunologicChildReceptorGeneticschemistry.chemical_classificationCross Infectioneducation.field_of_studyReceptors KIR3DL1Polymorphism Genetic; Models Molecular; Humans; Disease Progression; Gene Expression; HLA-B Antigens; Immunity Innate; Child; Receptors KIR3DL1; Protein Binding; HIV-1; Binding Sites; Receptors KIR3DS1; Receptors Immunologic; HIV Infections; Antigens CD; Protein Structure Tertiary; Signal Transduction; Amino Acid Substitution; Cross InfectionHLA-BCDAmino acidDisease ProgressionKIR3DL1Protein BindingSignal TransductionReceptors KIR3DS1Protein StructureImmunologyPopulationHuman leukocyte antigenBiologyGeneticKIR3DL1Antigens CDHumansPolymorphismAntigenseducationMolecular BiologySettore MED/04 - Patologia GeneralePolymorphism GeneticBinding SitesInnate immune systemImmunityMolecularImmunity InnateProtein Structure TertiaryAmino Acid SubstitutionchemistryHLA-B AntigensImmunologyHIV-1TertiaryMolecular Immunology
researchProduct

Exploratory study about needs of disease progression in cancer patients

Background: Oncological disease progression can be difficult to manage for physicians, due to therapeutic switch after a previous treatments’ failure, but also because oncologist have to be linked with information about clinical conditions for patient reassurance. Our research considers person an integrated system, looking at fundamental needs of patients, according to theoretical and empirical basis of Neo-functionalism in psychology. Several studies report more unmet needs in patients affected by cancer, despite an increased attention about bad news communication. Previous studies in the field of healthcare have shown that both communication and psychological characteristics of patients a…

Needs cancer disease progression illness perception quality of lifeSettore MED/06 - Oncologia Medica
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

2015

AbstractWe conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median su…

OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentECOG Performance StatusBone NeoplasmsYoung AdultInternal medicineCarcinomamedicine80 and overHumansYoung adultLung cancerNon-Small-Cell LungAgedLungMultidisciplinarybusiness.industryAdult Aged Aged 80 and over Bone Neoplasms Carcinoma Non-Small-Cell Lung Female Humans Lung Neoplasms Male Middle Aged Young Adult Disease Progression MultidisciplinaryCarcinomaBone metastasisMiddle Agedmedicine.diseaseRadiation therapymedicine.anatomical_structureConcomitantDisease ProgressionFemaleAdult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Young Adult; Disease Progressionbusiness
researchProduct